GlassScriptPhysician profile
Kathryn Kroeger
NPI 1952492779
$9,170.50
in general payments reported to CMS, 2019-2025
28 companies · $1,533 in 2025
The $1,533 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,929 · 2020: $1,045 · 2021: $759 · 2022: $1,135 · 2023: $1,241 · 2024: $1,528 · 2025: $1,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,237 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,236.73 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,295.04 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Abbvie INC. | $808.50 | 2019-2025 | |
| Genzyme Corporation | $703.71 | 2019-2025 | |
| Amgen INC. | $702.77 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $681.40 | 2019-2025 | Aklief, Epsolay, Oracea |
| Mayne Pharma Commercial LLC | $600.27 | 2019-2025 | |
| Pfizer INC. | $576.26 | 2019-2025 | |
| Incyte Corporation | $536.53 | 2021-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $478.12 | 2019-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $436.43 | 2019-2024 | Jublia, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $356.70 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $347.31 | 2019-2025 | |
| Lilly USA, LLC | $292.81 | 2019-2025 | Ebglyss, Taltz |
| Ucb, INC. | $292.80 | 2020-2025 | Bimzelx |
| Almirall LLC | $220.29 | 2019-2024 | Klisyri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $182.13 | 2019-2020 | |
| Leo Pharma INC. | $158.38 | 2019-2025 | Anzupgo, Adbry |
| Regeneron Healthcare Solutions, INC. | $142.56 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $71.52 | 2022-2023 | Vtama |
| Janssen Scientific Affairs, LLC | $49.90 | 2019-2022 | |
| Journey Medical Corporation | $48.26 | 2019-2025 | |
| Epi Health, LLC | $44.31 | 2019-2021 | |
| Celgene Corporation | $39.75 | 2019 | |
| Organon LLC | $35.95 | 2025 | Vtama |
| Prugen, INC. Pharmaceuticals | $24.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.52 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $11.87 | 2019 | |
| Aclaris Therapeutics, INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Kroeger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.